China Universal Asset Management Company’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

China Universal Asset Management Company’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-38	Closed	-$346	–	494
2023 Q3	$346	Buy	38 +19	+100%	+$382	﹤0.01%	446
2023 Q2	$408	Sell	19 -1	-5%	-$31	﹤0.01%	451
2023 Q1	$535	Buy	20 +5	+33%	+$233	﹤0.01%	446
2022 Q4	$527	Buy	15 +1	+7%	+$120	﹤0.01%	390
2022 Q3	$3K	Buy	+14	New	+$3.44K	﹤0.01%	341

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

China Universal Asset Management Company's EIGR Position: Q4 2023 in Review

China Universal Asset Management Company sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2023, closing a stake of 38 shares — an estimated $346 sold.

China Universal Asset Management Company first reported a position in EIGR in Q3 2022 and held it in 5 quarters. The position peaked at $3K in Q3 2022. 43 funds tracked by Wall St. Rank hold EIGR as of Q4 2023.

China Universal Asset Management Company reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
China Universal Asset Management Company sold 38 Eiger BioPharmaceuticals, Inc. shares in Q4 2023, an estimated $346.
China Universal Asset Management Company first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2022 and held it in 5 quarters.
China Universal Asset Management Company's Eiger BioPharmaceuticals, Inc. position peaked at $3K in Q3 2022.
43 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2023.

Based on China Universal Asset Management Company's 13F filing for Q4 2023, filed 24 Jan 2024.